• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oculis Holding AG - Ordinary shares (NQ:OCS)

26.00 +0.78 (+3.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 503,955
Open 24.95
Bid (Size) 24.00 (100)
Ask (Size) 26.50 (400)
Prev. Close 25.22
Today's Range 24.16 - 26.50
52wk Range 14.00 - 26.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
January 08, 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
January 06, 2026
From Oculis Holding AG
Via GlobeNewswire

Performance

YTD
+30.0%
+30.0%
1 Month
+27.8%
+27.8%
3 Month
+19.2%
+19.2%
6 Month
+47.5%
+47.5%
1 Year
+14.8%
+14.8%

More News

Read More
News headline image
Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
November 11, 2025
Via Benzinga
News headline image
Earnings Scheduled For November 6, 2025 ↗
November 06, 2025
Via Benzinga
News headline image
Uncovering Potential: Oculis Holding's Earnings Preview ↗
August 20, 2025
Via Benzinga
News headline image
Oculis Holding AG (NASDAQ:OCS) Reports Q3 2025 Earnings Beat and Provides Key Clinical Pipeline Updates ↗
November 10, 2025
Via Chartmill
Topics Earnings
News headline image
Oculis Reports Q3 2025 Financial Results and Provides Company Update
November 10, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming November Investor Conferences
November 05, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
October 30, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
October 14, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
October 08, 2025
Via Benzinga
News headline image
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
October 06, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
September 22, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
September 04, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
September 01, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming September Investor Conferences
August 28, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
This CoreWeave Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
August 27, 2025
Via Benzinga
News headline image
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
August 25, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Reports Q2 2025 Financial Results and Provides Company Update
August 21, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Earnings Scheduled For August 21, 2025 ↗
August 21, 2025
Via Benzinga
News headline image
Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 12, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Upsized Loan Facility to Access up to CHF 100 million
August 01, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Publishes Results of 2025 Annual General Meeting
June 05, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming June Investor Conferences
June 03, 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Publishes Invitation to the Annual General Meeting
May 09, 2025
From Oculis Holding AG
Via GlobeNewswire

Frequently Asked Questions

Is Oculis Holding AG - Ordinary shares publicly traded?
Yes, Oculis Holding AG - Ordinary shares is publicly traded.
What exchange does Oculis Holding AG - Ordinary shares trade on?
Oculis Holding AG - Ordinary shares trades on the Nasdaq Stock Market
What is the ticker symbol for Oculis Holding AG - Ordinary shares?
The ticker symbol for Oculis Holding AG - Ordinary shares is OCS on the Nasdaq Stock Market
What is the current price of Oculis Holding AG - Ordinary shares?
The current price of Oculis Holding AG - Ordinary shares is 26.00
When was Oculis Holding AG - Ordinary shares last traded?
The last trade of Oculis Holding AG - Ordinary shares was at 01/20/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap